Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. Recently, the BPI-572270 capsule clinical trial application declared by Hangzhou Jingyao Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, was approved by the US Food and Drug Administration (“US FDA”). This drug is intended for advanced solid tumors.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.